Related Experiment Videos
Endothelin and endothelin antagonists in hypertension
1Clinical Research Institute of Montréal (IRCM), Québec, Canada. schiffe@ircm.umontreal.ca
Journal of Hypertension
|January 14, 1999
Summary
Endothelin-1 contributes to hypertension and vascular growth in various rat models and human patients. Blocking endothelin receptors with antagonists shows promise for treating cardiovascular diseases like hypertension and heart failure.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- Endothelins (ET) are potent vasoconstrictor peptides, with ET-1 being the primary form secreted by the endothelium.
- ET-1 interacts with ETA and ETB receptors, influencing vascular smooth muscle contraction and the release of vasorelaxants like nitric oxide.
Discussion:
- ET-1 production is elevated in several experimental hypertension models, including DOCA-salt and Dahl salt-sensitive rats.
- Conversely, some hypertensive models like SHR and L-NAME-treated rats do not show an ET-1 component.
- Endothelin dependency is characterized by excessive vascular growth and is reversed by endothelin antagonists.
Key Insights:
- Endothelin antagonists, including orally active ETA/ETB or selective ETA inhibitors, are in clinical development.
- Human studies confirm endothelin-dependent vascular tone and enhanced ET-1 mRNA in hypertensive patients' small arteries.
- The combined ETA/ETB antagonist bosentan effectively reduced blood pressure in essential hypertension and improved hemodynamics in heart failure patients.
Outlook:
- Endothelin antagonists hold significant therapeutic potential for hypertension, heart failure, and primary pulmonary hypertension.
- The endothelin system's role in diverse cardiovascular diseases suggests broad applicability for its interruption.
- Further research into endothelin system modulation could yield novel treatments for cardiovascular pathologies.